Reported cash
Cash and cash equivalents · Restricted cash and marketable securities excluded
Cash verified Nov 16, 2026
Price chart
What changed?
No verified development in tracked sources.
Upcoming catalysts
Next verified event · FDA target date
ARIKAYCE · Mycobacterium avium complex · January 28, 2027
Mycobacterium avium complex (MAC) lung disease
Announced Oct 29, 2026
Official announcementSource wording
In September 2026, the U.S. Food and Drug Administration (FDA) accepted Insmed’s Supplemental New Drug Application (sNDA) for review of ARIKAYCE for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen. The FDA granted Priority Review to the sNDA and set a target action date of January 28, 2027, under the Prescription Drug User Fee Act (PDUFA).
Drug pipeline
0 programs · 0 verified studies
No verified studies linked yet.
56 unverified sponsor matches remain unlinked.
Verified timeline
0 recordsNo verified developments in tracked sources.